Annex™ Adjacent Level System for Treatment of Adjacent Level Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Locations
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28204
- Carolinas Neurosurgery and Spine
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Men or women 18-85 years of age
- Single level adjacent level segment disease (ALD) in the lumbar spine (L1-S1).
Exclusion Criteria:
- trauma, tumor, pseudoarthrosis, revision, or same-level recurrent stenosis
- cervical fusion candidates
- extraspinal cause of back pain
- local or systemic infection
- pregnant / able to become pregnant and not following a reliable contraceptive method
- Severe osteoporosis or osteopenia
- Morbid obesity defined as BMI > 40
- Anatomy or other factors that prohibit safe surgical access to the surgical site
- Allergy or sensitivity to any component of the treatment procedure
- Inadequate tissue coverage over the operative site
- Inadequate bone stock or bone quality
- Fever or leukocytosis
- Uncorrectable coagulopathy or hemorrhagic diathesis
- Cardiopulmonary conditions that present prohibitive anesthesia risk
- Neuromuscular disease or disorder
- Mental illness
- Has an active workman's compensation claim
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Other
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Annex Group
Patients prospectively treated with Annex™ Adjacent Level System
|
|
|
Retrospective Control
Patients previously treated for adjacent level disease using other systems
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
% Improvement in Operative/Discharge parameters including surgical time and hospital stay
Time Frame: within 30 days after treatment
|
within 30 days after treatment
|
|
Surgical Complication rate compared to retrospective chart review
Time Frame: Within 30 days of treatment
|
Within 30 days of treatment
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
% Pain reduction on VAS
Time Frame: Up to 2 years post-treatment
|
Up to 2 years post-treatment
|
|
% Improvement in Disability using ODI
Time Frame: Up to 2 years post-treatment
|
Up to 2 years post-treatment
|
|
% Improvement in Quality of Life using SF-36
Time Frame: Up to 2 years post-treatment
|
Up to 2 years post-treatment
|
|
% Patient Satisfaction with procedure
Time Frame: Up to 2 years post-treatment
|
Up to 2 years post-treatment
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- SW-ANX1401
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.